Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II study evaluating cadonilimab in combination with anlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung can...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II study evaluating cadonilimab in combination with anlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who progressed after prior PD-(L)1 inhibitor-based therapy.
智通财经获悉,一些冲击微软(MSFT.US)股价的不利因素短期内不太可能消退。高盛分析师Gabriela Borges在周一发布的一份最新报告中指出,今年以来微软股价下跌23%主要源于两个因素。首先,资本支出持续上调,但Azure云业务销售并未同步上修。这重新引发了市场对投资回报率以及Azure相对于竞争对手(如亚马逊的Amazon Web Services)竞争地位的担忧。其次,市场持续担忧微软...
How Modern Influence Operations Work, Part 1: The New Influence Stack Authored by Charles Davis via The Epoch Times, On a Tuesday night in a dorm room, a student opens TikTok for a “five-minute break.” The first clip is a montage of rubble and sirens. The second is a professor-style explainer, neatly captioned, delivering a single moral conclusion. The third is a shaky phone video of a confrontati...
How Modern Influence Operations Work, Part 1: The New Influence Stack Authored by Charles Davis via The Epoch Times, On a Tuesday night in a dorm room, a student opens TikTok for a “five-minute break.” The first clip is a montage of rubble and sirens. The second is a professor-style explainer, neatly captioned, delivering a single moral conclusion. The third is a shaky phone video of a confrontation on another campus—shouts, police lights, a crowd surging like weather. The student doesn’t search for any of it. They don’t even follow the accounts. The feed arrives already confident about what matters. This is the political technology of our moment: the system that decides—thousands of times a day—what you see next. The Influence Stack For most of the past century, influence meant broadcasting. You bought a newspaper, aired a radio spot, printed leaflets, argued in the town square. Feedback was slow, indirect, and expensive. Today, influence runs on a different stack. It is microtargeting—figuring out which slice of the population to target. It is recommender distribution—determining what to place in front of the target group and in what sequence. It is measurement of effects—watch time, rewatches, scroll-hesitation, comments, shares. And it is iteration—rapidly adjusting what works and discarding what doesn’t. Once those pieces lock together, persuasion stops looking like a party debate. It takes on the appearance of a thermostat: sense the room, nudge the temperature, sense again. Microtargeting Didn’t Begin With TikTok Microtargeting is older than the smartphone feed. Campaigns have long merged voter files with consumer and demographic data, then tailored appeals to specific segments. What changed, especially by the early 2010s, was tempo: the ability to see what’s working while the moment is still unfolding. The Obama campaign’s 2012 digital operation offers a useful bridge between the older world and the current one. Their teams watched web behavior in near real ...
78image/iStock via Getty Images It is a common occurrence to see the market fail to react to positive data or updates from small-cap healthcare companies. Admittedly, most of these companies are still very far from approval and are often undercapitalized to get their programs through the FDA and onto the market. However, I still get baffled when I see a company post clinical data that suggests the...
78image/iStock via Getty Images It is a common occurrence to see the market fail to react to positive data or updates from small-cap healthcare companies. Admittedly, most of these companies are still very far from approval and are often undercapitalized to get their programs through the FDA and onto the market. However, I still get baffled when I see a company post clinical data that suggests the drug/biologic/device/tech outperforms the standard of care in a huge market. Thankfully, some of these occurrences have allowed me to buy some shares at an apparent discount and eventually bank significant profit down the line as later-stage data confirms what was seen in the earlier studies. Well, Cardiff Oncology ( CRDF ) might turn out to be a great example after the market appeared to shrug off their recent Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). Five months ago, I wrote an article where I pointed out this data release to be a big catalyst for Cardiff, but perhaps I'm missing something. For me, the onvansertib in this dataset and conference call discussion suggests it is a drug that has a legitimate pathway to becoming a first-line standard-of-care backbone. As a result, I'm looking to take advantage of the market's lack of response and will look to add during this period of market volatility. I intend to review onvansertib's Phase II results and what the implications are for the drug, as well as the company. In addition, I discuss why I think the market reacted negatively to the data and the share price hasn't recovered. Then, I will point out some downside risks that investors need to consider when managing their CRDF position. Finally, I take a look at the daily chart to see if I can identify an opportunity to take advantage of the market's slip-up. Phase II Results The big headline for onvansertib's Phase II results was the 72% objective response rate (ORR), which is well above the 40%-45% range that is seen amon...